Cart
sales@molnova.com
Home - Products - Others - Other Targets - PH-064

PH-064

CAS No. 892546-37-1

PH-064 ( BIM-46187 )

Catalog No. M24916 CAS No. 892546-37-1

PH-064 is a heterotrimeric G-protein complex inhibitor.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 873 In Stock
50MG 1782 In Stock
100MG 2250 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock
Group Booking Get Quotation Bulk Inquiry Add to Cart

Biological Information

  • Product Name
    PH-064
  • Note
    Research use only, not for human use.
  • Brief Description
    PH-064 is a heterotrimeric G-protein complex inhibitor.
  • Description
    PH-064 is a heterotrimeric G-protein complex inhibitor.
  • Synonyms
    BIM-46187
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    heterotrimeric G-protein complex
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    892546-37-1
  • Formula Weight
    795.1
  • Molecular Formula
    C44H58N8O2S2
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    O=C([C@H](CSSC[C@@H](C(N1CCN2C([C@@H]1CC3CCCCC3)=NC(C4=CC=CC=C4)=C2)=O)N)N)N([C@H]5CC6CCCCC6)CCN(C5=N7)C=C7C8=CC=CC=C8
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Favre-Guilmard C, et al. The novel inhibitor of the heterotrimeric G-protein complex, BIM-46187, elicits anti-hyperalgesic properties and synergizes with morphine. Eur J Pharmacol. 2008 Oct 10;594(1-3):70-6.
Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog
related products

  • Raloxifene

    Raloxifene is a selective oestrogen receptor modulator. It has effects on bone and breast cancer and cardiovascular disease risk.

  • Oxymetholone

    Oxymetholone is an anabolic androgenic steroid and synthetic derivative of testosterone. Formulations containing oxymetholone are used in the treatment of anemias caused by deficient red cell production.

  • FIDAS-5

    FIDAS-5 effectively competes against S-adenosylmethionine (SAM) for MAT2A binding.?FIDAS-5 has anticancer activities.?FIDAS-5 is a potent and orally active methionine S-adenosyltransferase 2A (MAT2A) inhibitor with an IC50 of 2.1 μM.FIDAS-5 induces the expression of cell cycle inhibitor, p21WAF1/CIP1. FIDAS-5 (3 μM; 36 h) treatment reduces the levels of both S-adenosylmethionine (SAM) and S-adenosylhomocysteine (SAH) in LS174T cells.FIDAS-5 (3 μM; 7 days; LS174T cells) treatment significantly inhibits the proliferation of LS174T cells.

Sign In Join Free